Cargando…
Structure–activity exploration of a small-molecule Lipid II inhibitor
We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422293/ https://www.ncbi.nlm.nih.gov/pubmed/25987836 http://dx.doi.org/10.2147/DDDT.S79504 |
_version_ | 1782370034077663232 |
---|---|
author | Fletcher, Steven Yu, Wenbo Huang, Jing Kwasny, Steven M Chauhan, Jay Opperman, Timothy J MacKerell, Alexander D de Leeuw, Erik PH |
author_facet | Fletcher, Steven Yu, Wenbo Huang, Jing Kwasny, Steven M Chauhan, Jay Opperman, Timothy J MacKerell, Alexander D de Leeuw, Erik PH |
author_sort | Fletcher, Steven |
collection | PubMed |
description | We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]–N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure–activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency. |
format | Online Article Text |
id | pubmed-4422293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44222932015-05-18 Structure–activity exploration of a small-molecule Lipid II inhibitor Fletcher, Steven Yu, Wenbo Huang, Jing Kwasny, Steven M Chauhan, Jay Opperman, Timothy J MacKerell, Alexander D de Leeuw, Erik PH Drug Des Devel Ther Original Research We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]–N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure–activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency. Dove Medical Press 2015-04-24 /pmc/articles/PMC4422293/ /pubmed/25987836 http://dx.doi.org/10.2147/DDDT.S79504 Text en © 2015 Fletcher et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Fletcher, Steven Yu, Wenbo Huang, Jing Kwasny, Steven M Chauhan, Jay Opperman, Timothy J MacKerell, Alexander D de Leeuw, Erik PH Structure–activity exploration of a small-molecule Lipid II inhibitor |
title | Structure–activity exploration of a small-molecule Lipid II inhibitor |
title_full | Structure–activity exploration of a small-molecule Lipid II inhibitor |
title_fullStr | Structure–activity exploration of a small-molecule Lipid II inhibitor |
title_full_unstemmed | Structure–activity exploration of a small-molecule Lipid II inhibitor |
title_short | Structure–activity exploration of a small-molecule Lipid II inhibitor |
title_sort | structure–activity exploration of a small-molecule lipid ii inhibitor |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422293/ https://www.ncbi.nlm.nih.gov/pubmed/25987836 http://dx.doi.org/10.2147/DDDT.S79504 |
work_keys_str_mv | AT fletchersteven structureactivityexplorationofasmallmoleculelipidiiinhibitor AT yuwenbo structureactivityexplorationofasmallmoleculelipidiiinhibitor AT huangjing structureactivityexplorationofasmallmoleculelipidiiinhibitor AT kwasnystevenm structureactivityexplorationofasmallmoleculelipidiiinhibitor AT chauhanjay structureactivityexplorationofasmallmoleculelipidiiinhibitor AT oppermantimothyj structureactivityexplorationofasmallmoleculelipidiiinhibitor AT mackerellalexanderd structureactivityexplorationofasmallmoleculelipidiiinhibitor AT deleeuwerikph structureactivityexplorationofasmallmoleculelipidiiinhibitor |